The firm also said that it will restate its 2014 financial statements due to "errors related to the accounting for income taxes in our discontinued operations."
Abbott's first quarter diagnostic revenues decreased around 2 percent year over year, although its molecular diagnostic sales inched up a fraction of a percent.
The system uses off-the-shelf laboratory components and currently runs an Ebola assay based on isothermal amplification chemistry from Alere subsidiary TwistDx.
The deal includes PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab.
Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
The test is the second assay on the Alere i molecular platform, which was previously CLIA waived to run a flu test.
The investment bank maintained its stock ratings for Hologic, Cepheid, and T2 Biosystems.
The firms expanded their deal to develop a companion test for galeterone based on circulating tumor cell technology Qiagen has acquired from AdnaGen.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The assay is intended for early infant diagnosis of HIV infection.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.